Is Palvella Therapeutics, Inc. (PVLA) a Buy, Sell, or Hold?
NASDAQ : PVLA
Palvella Therapeutics, Inc.
$142.84 USD
$1.07 (0.75%)
- Volume
- 142.26K
- Average Volume
- 268.7K
- Market Capitalization
- $2.05B
- P/E Ratio
- -34.25
- Dividend Yield
- 0.00%
- Price Target
- $220.00
- Year High
- $161.38
- Year Low
- $34.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $28.88
Company Overview
NASDAQ
Wesley H. Kaupinen
Biotechnology
Healthcare
PVLA
29
US
USD
Liquidity Metrics
0.00
28.88
28.88
22.64
0.00
Sales & Valuation
-$
0.00
8.05
-70.40
-2.22
Profitability
-$3.71
-$41.72M
0.00%
0.00%
-56.87%
-18.69%
P/E Metrics
-34.25
-0.38
-0.38
Analyst Price Target & Rating
$220.00
$270.00
$210.00
2/5
11 Analysts
-35.07%
Financial Health Scores
38.57
2/9
$254.12M
$263.76M
$31.45M
-$46.73M
Key Metrics (TTM)
$1.83B
0.00
-49.99
28.88
-56.87%
-17.89%
-2.66%
-1.43%
0 days
Company Executives
| Name | Title |
|---|---|
| Sarah Foster | Senior Vice President of Human Resources |
| Kathleen Goin | Chief Operating Officer |
| Ashley Kline | Chief Commercial Officer |
| Bohan Wei | Vice President of Corporate Development & New Product Planning |
| Emily Cook | Senior Vice President of Clinical Operations |
| Jeffrey Martini | Chief Scientific Officer |
| Jason Burdette | SVP of CMC & Technical Operations |
| Kent Taylor | Senior Vice President of Sales |
| Matthew E. Korenberg | CFO, Corporate Secretary & Treasurer |
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Palvella Therapeutics, Inc. (NASDAQ:PVLA) Stock
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania. ...
2026-07-28 07:30:00
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
Fifth Third Bancorp Invests $2.49 Million in Palvella Therapeutics, Inc. $PVLA
2026-07-22 03:47:20
Fifth Third Bancorp bought a new stake in Palvella Therapeutics, Inc. (NASDAQ: PVLA) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,947 shares of the company's stock, valued at approximately $2,486,000. Fifth Third Bancorp owned approximately 0.14%
2026-06-30 07:30:00
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options
2026-06-29 07:30:00
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
2026-06-27 12:11:54
4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share. This was a derivative transaction involving the exercise and immediate sale of options.
2026-06-22 07:30:00
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted
2026-06-09 10:52:11
Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish
2026-06-05 07:30:00
Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They've also received some FDA feedback, which bodes well for their upcoming NDA submission. PVLA is now targeting a 2H2026 NDA submission for QTORIN rapamycin in mLM.
Frequently Asked Questions
-
What is the current Palvella Therapeutics, Inc. (PVLA) stock price?
-
Palvella Therapeutics, Inc.(NASDAQ:PVLA) stock price is $142.84 in the last trading session. During the trading session, PVLA stock reached the peak price of $161.38 while $34.57 was the lowest point it dropped to. The percentage change in PVLA stock occurred in the recent session was 0.75% while the dollar amount for the price change in PVLA stock was $1.07.
-
PVLA's industry and sector of operation?
-
The NASDAQ listed PVLA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PVLA?
-
Sarah Foster | Senior Vice President of Human Resources
Kathleen Goin | Chief Operating Officer
Ashley Kline | Chief Commercial Officer
Bohan Wei | Vice President of Corporate Development & New Product Planning
Emily Cook | Senior Vice President of Clinical Operations -
How many employees does PVLA have?
-
Number of PVLA employees currently stands at 29. PVLA operates from 125 Strafford Avenue, Wayne, PA 19087, US.
-
Link for PVLA official website?
-
Official Website of PVLA is: https://palvellatx.com
-
How do I contact PVLA?
-
PVLA could be contacted at phone #484 253 1461 and can also be accessed through its website. PVLA operates from 125 Strafford Avenue, Wayne, PA 19087, US.
-
How many shares of PVLA are traded daily?
-
The average number of PVLA shares traded daily for last 3 months was 268.7K.
-
What is the market cap of PVLA currently?
-
The market value of PVLA currently stands at $2.05B with its latest stock price at $142.84